Phospholipid (Cardiolipin) Antibodies, IgA, Serum
Use
This test may be of diagnostic significance for patients at risk for antiphospholipid syndrome (APS) or systemic lupus erythematosus (SLE) who test negative for criterial antiphospholipid antibodies. APS is characterized by thrombosis and/or pregnancy-related morbidities associated with persistent positivities of aPL antibodies. It is crucial for determining APS and often tested alongside other aPL antibody tests, such as lupus anticoagulant (LAC) and IgG/IgM to cardiolipin and anti-beta2-glycoprotein I. Testing is recommended for noncriteria aPL antibody tests in cases with high disease suspicion but inconclusive results using other criteria.
Special Instructions
Not provided.
Limitations
Immunoassays used may not completely distinguish between autoantibodies for APS and those from infectious responses. Evaluation of results may vary with different commercial assays. Interpretation should consider persistence based on Sapporo criteria. Measurement of aCL and anti-B2GPI IgA lacks formal guidance, and clinical relevance of isolated IgA is minimal. Transient antibody production and variability between assay types should be accounted for in clinical practice.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 5076-5 - Cardiolipin IgA Ser IA-aCnc
- 5076-5 - Cardiolipin IgA Ser IA-aCnc
Result Turnaround Time
3-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.4 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis, gross lipemia, heat-treated specimen
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 21 days |
| Frozen | 21 days |